Wed. 7 Feb 2024, 7:33am ET
Benzinga
News
The patents, which are expected to provide exclusivity until at least 2040 and 2041, respectively, include protection for a synthesis method for the preparation of DMT and dDMT and injectable formulations within the Company's proprietary DMT program in clinical development for the treatment of Generalized Anxiety Disorder.